Management of acneiform rash associated with anti-EGFR monoclonal antibody treatment
https://doi.org/10.21518/2079-701X-2020-20-157-164
Abstract
Introduction. Dermatologic adverse events (DAEs) occur in 50-90% of cases during anti-EGFR monoclonal antibody treatment. Positive correlation between the severity of acneiform rash (AR) and the effectiveness of anti-EGFR management is established. Low effectiveness of traditional treatment for AR impairs patients’ compliance, leads to dose reduction or drug discontinuation, affecting treatment results.
Objective. To assess the effectiveness of traditional and proposed combined treatment for AR associated with anti-EGFR monoclonal antibody therapy.
Materials and methods. 44 patients with grade I-II acneiform rash were included in a 12-week study. Patients were divided into 3 equal groups and received different treatment: group 1a – traditional therapy, group 1b – combined continuous therapy, and group 1c – combined intermittent therapy. Assessment of clinical outcomes was performed with DLQI, IGA score, and the NCI CTCAE v. 4.03.
Results. The severity of AR in groups 1b and 1c improved by the end of week 1, and this trend was kept until the end of the study. The improvement was more prominent in group 1c comparing to group 1b. The severity of AR in group 1a improved by the end of week 1. During weeks 2 and 3 there was no significant change. At week 4 a deterioration of the evaluated parameters was registered, and the treatment regimen in group 1a was changed according to the treatment protocols of group 1c with rapid improvement of AR.
Conclusion. Combined intermittent therapy with systemic doxycycline and topical therapy with metronidazole 1% gel and cream with hydrocortisone acetate 1% and fusidic acid 2% showed the best effectiveness and tolerability in patients with anti-EGFR monoclonal antibody-related AR.
About the Authors
E. A. Shatokhina
Central State Medical Academy;
Medical Center
Russian Federation
Russian Federation
Evgeniya A. Shatokhina, Cand. of Sci, (Med.), Associate Professor, Department of Dermatovenereology and Cosmetology, Central State Medical Academy; 19, Dermatovenerologist, Clinical Diagnostic Department, Medical Research and Educational Cente
Bldg. 1a, Marshal Timoshenko St., Moscow, 121359, Russia;
27/10, Lomonosovskiy Ave., Moscow, 119192, Russia
L. S. Kruglova
Central State Medical Academy
Russian Federation
Russian Federation
Larisa S. Kruglova, Dr. of Sci. (Med.), Head of Department of Dermatovenereology and Cosmetology
Bldg. 1a, Marshal Timoshenko St., Moscow, 121359, Russia
A. S. Polonskaia
Central State Medical Academy
Russian Federation
Russian Federation
Aleksandra S. Polonskaia, Postgraduate Student, Department of Dermatovenereology and Cosmetology
Bldg. 1a, Marshal Timoshenko St., Moscow, 121359, Russia
References
1. Kaprin A.D., Starinsky V.V., Petrova G.V. (eds.). Malignant tumors in Russia in 2017 (incidence and mortality). Moscow: FSBI NMRRC of the Ministry of Health of the Russian Federation; 2018. (In Russ.) Available at: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf.
2. Tyulyandin S.A. Targeted therapy: twenty years of success and failure. Prakticheskaya onkologiya = Practical Oncology. 2019;20(4):274–288. (In Russ.) doi: 10.31917/2004274.
3. Fedyanin M.Yu., Gladkov O.A., Gordeev S.S., Rykov I.V., Tryakin A.A. et al. Practical recommendations on medicamentous treatment of colon cancer and cancer of rectosigmoid junction. Zlokahestvennye opukholi: Prakticheskie rekomendacii RUSSCO = Malignant Tumors: Practical Recom mendations RUSSCO. 2019;9(3s2):324–364. (In Russ.) Available at: https://rosoncoweb.ru/standarts/RUSSCO/2019/2019-21.pdf.
4. Tsimafeyeu I.V., Varlamov I.S., Petkau V.V., Safina S.Z., Zukov R.A. et al. Life expectancy in patients with metastatic renal cell carcinoma in the Russian Federation: results of the RENSUR3 multicenter registry study. Zlokachestvennye opukholi = Malignant Tumours. 2019;9(2):45–52. (In Russ.) doi: 10.18027/2224-5057-2019-9-2-45-52.
5. Isyangulova A.Z., Khasanov R.Sh., Enikeev R.F. Targeted therapy for gastrointestinal and pancreatic neuroendocrine tumors. Zlokachestvennye opuk holi = Malignant Tumours. 2019;9(4):49–58. (In Russ.) doi: 10.18027/2224-5057-2019-9-4-49-58.
6. Le T., Gerber D.E. Newer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used? Cancers (Basel). 2019;11(3):366. doi: 10.3390/cancers11030366.
7. Pérez-Soler R., Delord J.P., Halpern A., Kelly K., Krueger J., Sureda B.M. et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005;10(5):345–356. doi: 10.1634/theoncologist.10-5-345.
8. Bouché O., Scaglia E., Reguiai Z., Singha V., Brixi-Benmansour H., Lagarde S. Targeted biotherapies in digestive oncology: management of adverse effects. Gastroenterol clint biol. 2009;3(4)3:306–322. doi: 10.1016/j.gcb.2009.02.008.
9. Melosky B., Burkes R., Rayson D., Alcindor T., Shear N., Lacouture M. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr oncol. 2009;16(1):16–26. doi: 10.3747/co.v16i1.361.
10. Potthoff K., Hofheinz R., Hassel J.C., Volkenandt M., Lordick F., Hartmann J.T. et al. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol. 2011;22(3):524–535. doi: 10.1093/annonc/mdq387.
11. Segaert S., Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16(9):1425–1433. doi: 10.1093/annonc/mdi279.
12. Lynch T.J. Jr., Kim E.S., Eaby B., Garey J., West D.P., Lacouture M.E. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2006;12(5):610–621. doi: 10.1634/theoncologist.12-5-610.
13. Guillot B., Bessis D. Aspects cliniques et priseen charge des effets secondaires cutanés des inhibiteurs du récepteur à l’EGF. Annales de Dermatologie et de Venereologie. 2006;133(12):1017–1020. doi: 10.1016/S0151-9638(06)71093-6.
14. Boers-Doets C.B., Gelderblom H., Lacouture M.E., Epstein J.B., Nortier J.W.R., Kaptein A.A. Experiences with the FACT-EGFRI-18 instrument in EGFRIassociated mucocutaneous adverse events. Support Care Cancer. 2013;21(7):1919–1926. doi: 10.1007/s00520-013-1752-4.
15. Nardone B., Hensley J.R., Kulik L., West D.P., Mulcahy M., Rademaker A., Lacouture M.E. The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life. J Drugs Dermatol. 2012;11(11):e61–e65. Available at: https://pubmed.ncbi.nlm.nih.gov/23135095/.
16. Teo Y.L., Chong X.J., Chue X.P., Chau N.M., Tan M.H., Kanesvaran R. et al. Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation. Cancer Chemother Pharmacol. 2014;73(2):381–388. doi: 10.1007/s00280-013-2360-1.
17. Broekman F., Giovannetti E., Peters G.J. Tyrosine kinase inhibitors: Multitargeted or single-targeted? World J Clin Oncol. 2011;2(2):80–93. doi: 10.5306/wjco.v2.i2.80.
18. Lacouture M.E., Anadkat M.J., Bensadoun R.J., Bryce J., Chan A., Epstein J.B. et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079–1095. doi: 10.1007/s00520-011-1197-6.
19. Liu H.B., Wu Y., Lv T.F., Yao Y-w., Xiao Y.-Y., Yuan D.-M., Song Y. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2013;8(1):e55128. doi: 10.1371/journal.pone.0055128.
20. Peeters M., Siena S., Van Cutsem E. Sobrero A., Hendlisz A., Cascinu S. et al. Association of progression-free survival, overall survival, and patient-reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy. Cancer. 2009;115(7):1544–1554. doi: 10.1002/cncr.24088.
21. Racca P., Fanchini L., Caliendo V., Ritorto G., Evangelista W., Volpatto R. et al. Efficacy and skin toxicity management with cetuximab in metastatic colorectal cancer: outcomes from an oncologic/dermatologic Cooperation. Clin Colorectal Cancer. 2008;7(1):48–54. doi: 10.3816/CCC.2008.n.007.
22. Hofheinz R.D., Segaert S., Safont M.J., Demonty G., Prenen H. Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors. Crit Rev Oncol Hematol. 2017;114:102– 113. doi: 10.1016/j.critrevonc.2017.03.032.
23. Kim Y.S., Ji J.H., Oh S.Y., Lee S., Huh S.J., Lee J.H. et al. A randomized controlled trial of epidermal growth factor ointment for treating epidermal growth factor receptor inhibitor-induced skin toxicities. Oncologist. 2020;25(1):e186–е193. doi: 10.1634/theoncologist.2019-0221.
24. Andrews E.D., Garg N., Patel A.B. A retrospective chart review on oral retinoids as a treatment for epidermal growth factor receptor inhibitorand mitogenactivated protein kinase kinase inhibitor-induced acneiform eruptions. J Am Acad Dermatol. 2020;82(4):998–1000. doi: 10.1016/j.jaad.2019.10.003.
25. Kochergin N.G., Kochergin S.N. Indices of the scale of symptoms and quality of life in dermatology. In: Materials of the VIII AllRussian Congress of Dermato venerologists. Moscow, June 19–22, 2001. Part 1. Moscow; 2001. (In Russ.).
26. Finlay A.Y. Quality of life in dermatology: after 125 years, time for more rigorous reporting. Br J Dermatol. 2014;170(1):4–6. doi: 10.1111/bjd.12737.
27. Finlay A.Y., Khan G.K. Dermatology life quality index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x.
Review
For citations:
Shatokhina EA, Kruglova LS, Polonskaia AS. Management of acneiform rash associated with anti-EGFR monoclonal antibody treatment. Meditsinskiy sovet = Medical Council. 2020;(20):157-164. (In Russ.) https://doi.org/10.21518/2079-701X-2020-20-157-164
Views:
601
Email this article 